Ureteroscopic Laser Modality on Total Lasing Time and Total Energy in Patients With Large, Dense Renal Calculi
NCT ID: NCT05869890
Last Updated: 2025-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
2 participants
INTERVENTIONAL
2023-02-22
2024-08-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MOSES Lithotripsy Technology Applied to Stone Fragmentation During Ureteroscopy
NCT03995758
Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings
NCT02683993
The Performance of the SOLTIVE Laser System for Laser Lithotripsy in Kidney or Ureteral Stones
NCT04556201
"Dusting" Versus "Basketing" - Treatment Of Intrarenal Stones
NCT01619735
Thulium Fiber Laser (TFL) Versus Holmium MOSES Laser for Ureteroscopic Management of Kidney Stones
NCT05598645
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Flexible Ureteroscopy with Dusting
Flexible ureteroscopy with the dusting lasing technique. MOSES parameters will be set to an energy of 0.3-0.4 Jules and a frequency of 50-80 hertz
MOSES laser system
A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,
Flexible Ureteroscopy with Fragmentation
Flexible ureteroscopy utilizing the Fragmentation lasing technique. MOSES parameters will be set to 0.8-1 JULES and a frequency of 8-10 hertz
MOSES laser system
A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,
Flexible Ureteroscopy with Hybrid
Flexible ureteroscopy utilizing the Hybrid lasing technique which will use both sets of parameters.
MOSES laser system
A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MOSES laser system
A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any gender, race or ethnicity may be included- these factors play a small, if any role on renal calculi formation and ability to withstand procedure.
* Must be suitable for a flexible ureteroscopy as determined by the MD
* Large renal calculi burden of single or multiple stones with the sum of its longest diameters between 10-20 mm
* An average stone density of at least 1000 Hounsfield units.
Exclusion Criteria
* Those with an average stone density below 1000 Hounsfield units.
* Patients who are dependent on mandatory anticoagulation therapies and cannot stop for surgery
* Patients that cannot undergo ureteral access sheath placement
* Patients with abnormal anatomy such as horseshoe kidney
* Patients with a history of:
* Ipsilateral upper urinary tract reconstructive procedures on the side of the renal calculi
* Ipsilateral ureteral strictures
* Prior radiotherapy of the abdomen or pelvis
* Neurogenic bladder
* Spinal cord injuries
* Those who are pregnant
* Currently being treated for infection or cancer
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Albany Medical College
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brenda Romeo
Research Manager for Luay Alshara
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Albany Medical College
Albany, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6286
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.